Arbutus Biopharma Corporation
ABUS
$4.58
$0.173.86%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 2,889.93% | 128.21% | 116.64% | 53.23% | -50.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2,889.93% | 128.21% | 116.64% | 53.23% | -50.69% |
| Cost of Revenue | -57.13% | -53.29% | -53.74% | -45.35% | -32.80% |
| Gross Profit | 515.25% | 76.69% | 74.24% | 62.26% | 28.79% |
| SG&A Expenses | -29.51% | -28.11% | -24.81% | -22.66% | 1.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -48.23% | -45.98% | -46.11% | -39.51% | -24.54% |
| Operating Income | 343.02% | 61.34% | 60.08% | 50.83% | 20.30% |
| Income Before Tax | 309.90% | 52.09% | 44.88% | 29.62% | -2.94% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 309.90% | 52.09% | 44.88% | 29.62% | -2.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 309.90% | 52.09% | 44.88% | 29.62% | -2.94% |
| EBIT | 343.02% | 61.34% | 60.08% | 50.83% | 20.30% |
| EBITDA | 348.37% | 61.09% | 60.24% | 51.20% | 20.58% |
| EPS Basic | 305.07% | 53.56% | 47.91% | 35.30% | 7.97% |
| Normalized Basic EPS | 368.27% | 65.01% | 64.98% | 57.52% | 30.58% |
| EPS Diluted | 299.83% | 52.93% | 47.53% | 35.09% | 6.79% |
| Normalized Diluted EPS | 366.18% | 65.01% | 64.98% | 57.52% | 30.58% |
| Average Basic Shares Outstanding | 1.59% | 3.24% | 5.89% | 8.74% | 11.75% |
| Average Diluted Shares Outstanding | 1.89% | 3.35% | 6.01% | 8.87% | 11.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |